Fabtech Technologies IPO is set to open from September 29 to October 1, 2025, with a price band of ₹181 to ₹191 per share and a lot size of 75 shares. The IPO aims to raise ₹230.35 crore through a fresh issue, seeking to fuel growth in the pharmaceutical and biotech infrastructure segments. The Fabtech Technologies IPO offers investors access to a niche sector with significant global growth potential driven by expanding pharma manufacturing and regulatory compliance needs.
₹00
₹191
₹192.00
Expert Opinions
Market sentiment toward Fabtech Technologies IPO remains strong, reflecting high investor interest due to consistent revenue growth and expanding global footprint in pharmaceutical engineering. Fabtech’s strengths include a robust order book across 62 countries, specialization in turnkey cleanroom solutions for pharma and biotech, and an asset-light business model that enhances capital efficiency.
The company’s valuation for financial year 2025 in this Fabtech Technologies IPO indicates a Return on Equity (ROE) of 30.46%, Return on Capital Employed (ROCE) of 24.46%, and a Net Asset Value (NAV) of ₹53.44, underscoring healthy profitability and efficient capital use. Risks include dependency on a limited set of customers and sensitivity to regulatory changes in pharma sectors. Overall, Fabtech Technologies provides a promising long-term investment opportunity in the growing healthcare infrastructure market, though short-term listing volatility should be considered.
Investor Considerations
Fabtech Technologies IPO presents a compelling investment opportunity backed by strong company performance and fundamentals. The company has shown robust revenue growth of 44% to ₹335.94 crore in FY 2025, with profit after tax rising by 71% to ₹46.45 crore, reflecting solid operational efficiency and margin expansion. The sector outlook for pharmaceutical and biotech infrastructure remains promising, driven by increased global demand for compliant, high-quality manufacturing facilities.
In the Fabtech Technologies IPO valuation for financial year 2025, the Price to Book Value stands at 3.57, PAT Margin at 13.83%, and Debt to Equity ratio at 0.32, indicating manageable leverage with good profitability. Growth prospects are supported by a strong order book, global expansion, and increasing healthcare investments. Risks include high customer concentration and exposure to regulatory changes. The IPO is suited for long-term investors focusing on sector growth, while short-term investors should consider market volatility.
| Date | GMP | Trend |
|---|---|---|
| 06 Oct 2025 11.37 | ₹00 | --- |
| 04 Oct 2025 11.24 | ₹00 | --- |
| 03 Oct 2025 12.07 | ₹00 | --- |
| 01 Oct 2025 12.50 | ₹00 | Down |
| 29 Sep 2025 19.45 | ₹2 | Up |
| 28 Sep 2025 19.22 | ₹00 | --- |
FAQs
The Grey Market Premium showed fair accuracy in predicting Fabtech Technologies IPO’s listing performance. With a final GMP of ₹0, it projected no premium or discount over the issue price of ₹191. The stock, however, listed at ₹192, delivering a marginal gain of 0.52%. This resulted in a small prediction error of 0.52%, where the GMP correctly signaled a stable listing and closely aligned with the actual outcome, reflecting fair reliability in this case.
Fabtech Technologies IPO Current GMP is ₹00.
Fabtech Technologies IPO Expected Returns is 0.00%.
Fabtech Technologies IPO estimated listing price is ₹191.